Companies › Eli Lilly › R&D expense

Eli Lilly research and development expense, 2008–2025

Eli Lilly reported research and development expense of $13.3 billion for the fiscal year ended Dec. 31, 2025, up 21.3% from $11.0 billion the year before, according to its Form 10-K.

$13.3Blatest fiscal year (ended Dec. 31, 2025)
+21.3%change from the year before
$13.3Bhighest year shown (2025)
2008: $3.84B ’08 2009: $4.33B 2010: $4.88B ’10 2011: $5.02B 2012: $5.28B ’12 2013: $5.53B 2014: $4.73B ’14 2015: $4.80B 2016: $5.31B ’16 2017: $5.10B 2018: $5.05B ’18 2019: $5.59B 2020: $5.98B ’20 2021: $6.93B 2022: $7.19B ’22 2023: $9.31B 2024: $11.0B ’24 2025: $13.3B ’25

Fiscal years labeled by the year in which they ended. Bars drawn from the table below.

Eli Lilly research and development expense by fiscal year

Fiscal year endedR&D expenseChangeFiling
Dec. 31, 2025 $13.3B +21.3% 10-K (2026) ↗
Dec. 31, 2024 $11.0B +18.0% 10-K (2026) ↗
Dec. 31, 2023 $9.31B +29.5% 10-K (2026) ↗
Dec. 31, 2022 $7.19B +3.8% 10-K (2023) ↗
Dec. 31, 2021 $6.93B +16.0% 10-K (2023) ↗
Dec. 31, 2020 $5.98B +6.8% 10-K (2023) ↗
Dec. 31, 2019 $5.59B +10.8% 10-K (2022) ↗
Dec. 31, 2018 $5.05B −0.9% 10-K (2021) ↗
Dec. 31, 2017 $5.10B −4.0% 10-K (2020) ↗
Dec. 31, 2016 $5.31B +10.7% 10-K (2019) ↗
Dec. 31, 2015 $4.80B +1.3% 10-K (2018) ↗
Dec. 31, 2014 $4.73B −14.4% 10-K (2017) ↗
Dec. 31, 2013 $5.53B +4.8% 10-K (2016) ↗
Dec. 31, 2012 $5.28B +5.1% 10-K (2015) ↗
Dec. 31, 2011 $5.02B +2.8% 10-K (2014) ↗
Dec. 31, 2010 $4.88B +12.9% 10-K (2013) ↗
Dec. 31, 2009 $4.33B +12.6% 10-K (2012) ↗
Dec. 31, 2008 $3.84B — 10-K (2011) ↗

Other Eli Lilly financials

RevenueNet incomeDiluted EPSOperating cash flowDividends per shareDiluted sharesTotal assetsCash and equivalentsStockholders' equity Quarterly results and next earnings date Eli Lilly company hub

FAQ

Q What was Eli Lilly's research and development expense in its latest fiscal year?

A Eli Lilly reported research and development expense of $13.3 billion for the fiscal year ended Dec. 31, 2025, up 21.3% from $11.0 billion the year before, according to its Form 10-K.

Q What is Eli Lilly's highest annual research and development expense on record here?

A $13.3 billion, in the fiscal year ended Dec. 31, 2025, among the fiscal years 2008–2025 reported in its 10-K XBRL data.

Q Where does this research and development expense data come from?

A From Eli Lilly's annual reports on Form 10-K, as tagged in XBRL and published by the SEC (company facts). Research and development expense as reported in the income statement.

Source: Eli Lilly's annual reports on Form 10-K via SEC XBRL company facts, updated Oct. 15, 2026. Research and development expense as reported in the income statement. For each year the most recent 10-K that reports it is used, so a figure a company later restated shows the restated value; the filing link shows which report it came from. Change is our arithmetic. Financial data, not investment advice.